Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results
August 10, 2017 08:50 ET
|
Madrigal Pharmaceuticals, Inc.
- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH - - Raised $35 million...
Associates in Cardiovascular Disease and Admera Health Unveiled a Health Economics Model at the 2017 National Lipid Association Conference Detailing the Cost Benefits of Genetic Testing for Familial Hypercholesterolemia
May 23, 2017 09:25 ET
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., May 23, 2017 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company developing comprehensive genetic tests for risk assessment and early diagnosis of...
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196
April 03, 2017 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
- MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, has the potential to treat NASH (non-alcoholic steatohepatitis) and familial hypercholesterolemia (FH) - -...
PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference
February 07, 2017 09:30 ET
|
National Lipid Association
PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...
Admera Health Launches Molecular Test for Inherited Early Atherosclerosis Diagnosis and Risk
March 17, 2016 07:00 ET
|
Admera Health, LLC
SOUTH PLAINFIELD, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), a commercial stage New Jersey based Precision Medicine and Digital Health company announced today the...
Aegerion Pharmaceuticals Observes Rare Disease Day
February 28, 2013 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
January 07, 2013 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
December 24, 2012 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...